Clyde Biosciences Ltd.

Clyde Biosciences is an official member of the CiPA consortium, and a Core Group member contributing towards the development of the next generation of assays.

We run drug screening studies on our CellOPTIQ® system using the accepted CiPA Protocol. Only Clyde can provide you with a rapid-turnaround VSD screening study on your compounds.

Clyde works with virtually all of the major suppliers of iPS-CMs to characterise their cells on using the standard CiPA protocol. These data provide an invaluable reference point for the performance of cells. CellOPTIQ® works with 2D and 3D structures.

Major benefits include:

• Drug screening using a standard CiPA protocol
  
• iPS-CM characterisation studies using CiPA 8 (first phase CiPA)
  
• iPS-CM characterisation studies using CiPA 28 (second phase CiPA)

Clyde Biosciences works with the leading manufacturers of iPS-CMs to provide a broad dataset of parameters, enabling companies to understand the performance of their cells in the context of drug testing.

These data are essential for iPS-CM suppliers to communicate accurately the characteristics of their cells to biopharma companies.

Clyde’s Approach:

• Clyde Biosciences’ CellOPTIQ™ system measures calcium, voltage and contractility in the same cells
  
• Using ratiometric dyes, CellOPTIQ™ can make measurements which are unaffected by movement artefact or variations in cell thickness
  
• This means data are more accurate, with significantly reduced signal-to-noise

hiPSC-CM - Human induced pluripotent stem cell-derived cardiomyocytes

Clyde is able to provide our clients with access to the highest quality ion channel screening technology

Clyde’s Ion Channel Service:

The Rational Approach

• Clyde partners with the industry’s leading specialist ion channel providers
  
• Provide CiPA-ready data combining outputs from all assay modalities in one project